EQS-Ad-hoc: AT&S Austria Technologie & Systemtechnik AG / Key word(s): Change in Forecast
AT&S increases guidance for the current financial year 2022/23
Disclosure of inside information according to Article 17 MAR
Leoben –AT & S Austria Technologie & Systemtechnik Aktiengesellschaft has essentially adjusted three of its assumptions regarding the future development within the current financial year:
Therefore, AT&S anticipates that revenue of roughly € 2.2 billion will be generated in the financial year 2022/23 (previously: approx. € 2 billion). The expected EBITDA margin adjusted for start-up costs will increase to 27 to 30% (previously: 23 to 26%). The assumptions regarding start-up costs (€ 75 million) and the investment volume (€ 1,250 million) remain unchanged. The outlook is based on the assumption that the global economy will not enter a recession, no direct negative financial effects of the geopolitical upheavals will result from the war in Ukraine and the Covid situation in China will not lead to any long-term production downtimes.
AT & S Austria Technologie & Systemtechnik Aktiengesellschaft – Advanced Technologies & Solutions
Press contact: Gerald Reischl, Director Communications & Public Relations Tel: +43 3842 200 4252; Mobile: +43 664 8859 2452; g.reischl@ats.net
Investor Relations contact: Philipp Gebhardt, Director Investor Relations Tel: +43 3842 200 2274; Mobile: +43 664 7800 2274; p.gebhardt@ats.net
AT & S Austria Technologie & Systemtechnik Aktiengesellschaft Fabriksgasse 13
20-Jun-2022 CET/CEST News transmitted by EQS Group AG. www.eqs.com |
Language: | English |
Company: | AT&S Austria Technologie & Systemtechnik AG |
Fabriksgasse 13 | |
8700 Leoben | |
Austria | |
Phone: | +43 (1) 3842200-0 |
E-mail: | ir@ats.net |
Internet: | www.ats.net |
ISIN: | AT0000969985, AT0000A09S02 |
WKN: | 922230 |
Indices: | ATX |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Official Market) |
EQS News ID: | 1379551 |
End of Announcement | EQS News Service |
|
1379551 20-Jun-2022 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.